LifeMD vs Ro for GLP-1 Weight Loss (2026)

LifeMD vs Ro for GLP-1 Weight Loss (2026)

Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.

Pricing and protocol data sourced from LifeMD's and Ro's public websites, verified April 2026. We have no commercial relationship with either provider.

LifeMD (NASDAQ: LFMD) and Ro are both large, publicly visible DTC telehealth companies that have made brand-name GLP-1 access central to their weight management programs. The structural difference between them is one line item: LifeMD charges a program fee on top of medication costs; Ro does not. That fee — $75 in month one, $149/month thereafter for self-pay patients — means LifeMD's all-in monthly cost is higher than Ro's at every comparable medication tier. What patients get in return is video consultation availability, in-house prior authorization handling, and lab work through Labcorp and Quest — clinical infrastructure that Ro's asynchronous model does not include.

Self-pay patients who want the lowest monthly bill will find Ro cheaper. Patients with PPO insurance or who want synchronous clinical care are paying LifeMD's program fee for services Ro does not provide.

---

Quick verdict

	LifeMD	Ro
Program fee	$75/mo (month 1), $149/mo thereafter	None
Insurance accepted	✅ Most PPO plans	Partial (navigation only)
Video consultations	✅ Available within 1 hr ($50/visit)	❌ Async-only
Prior authorization handled in-house	✅	❌
Lab work included	✅ Labcorp/Quest	❌
Oral Wegovy	✅	✅
Brand Wegovy injectable	✅ Novo Nordisk partnership	✅ $349/mo cash-pay
Brand Zepbound	✅ $349/mo (2.5mg) via LillyDirect	✅ Via insurance
Orforglipron (PDUFA April 10, 2026)	✅ $149/mo announced	✅ $149/mo expected
Compounded semaglutide	❌	✅ $149/mo
Triple Therapy (non-GLP-1 oral)	✅ $129/mo	❌
HSA/FSA eligible	✅	✅

Choose LifeMD if: You have PPO insurance that covers GLP-1 medications, you want video consultation availability, or you're interested in brand-name brand GLP-1s with in-house insurance navigation. LifeMD's program fee drops to $29/mo for qualifying insured patients — making it potentially cheaper all-in than Ro for patients whose plans cover Wegovy.

Choose Ro if: You're paying out of pocket, you want the lowest monthly cost from a major established platform, or you want access to compounded semaglutide at $149/month with no add-on fees.

---

Which is cheaper: LifeMD or Ro?

For self-pay patients, Ro is cheaper across every medication tier. LifeMD's program fee — $75 in month one, then $149/month for standard self-pay patients — applies on top of medication costs, making its all-in monthly cost higher than Ro's equivalent offering. At the entry tier, Ro's $149/month compounded semaglutide beats LifeMD's lowest self-pay path ($149/mo medication + $75/mo fee = $224/mo, orforglipron pending approval) by $75/month in the first month, and by $149/month in subsequent months if you're comparing to the compounded tier.

For insured patients with PPO coverage, LifeMD can be cheaper. When qualifying insurance is in place, LifeMD's program fee drops to $29/month, and brand Wegovy or Zepbound may cost $0–$75/month at copay — making the all-in cost potentially under $105/month for well-covered patients. Ro has no program fee, but it also does not handle prior authorization internally at the same depth as LifeMD. The practical difference: patients who need help getting insurer approval tend to find LifeMD's dedicated insurance navigation team worth the difference.

Pricing last verified April 2026. We update pricing data monthly.

Medication	LifeMD all-in (self-pay)	Ro all-in (self-pay)
Compounded semaglutide	❌ Not offered	$149/mo
Orforglipron (pending FDA approval, PDUFA April 10)	~$224/mo ($149 med + $75 fee, mo. 1)	~$149/mo expected post-approval
Oral Wegovy (4mg)	~$274/mo ($199 + $75 fee)	$149/mo through April 15, then $199/mo
Oral Wegovy (9–25mg)	~$448/mo ($299 + $149 fee, ongoing)	$299/mo
Brand Wegovy injectable	Starting at $348/mo ($199+ med + $149 fee, ongoing)	$349/mo cash-pay
Zepbound (2.5mg)	~$498/mo ($349 + $149 fee, ongoing)	$299/mo via LillyDirect
Triple Therapy (non-GLP-1)	~$278/mo ($129 + $149 fee, ongoing)	❌ Not offered
With qualifying PPO insurance	$29/mo program fee + copay	No program fee + copay

Important note on LifeMD's program fee: LifeMD advertises $75/month as an introductory rate. Verified April 2026 on lifemd.com, the site states "$75 for your first month, and just $149 a month thereafter." Build the $149/month ongoing rate into your cost calculation — the $75/month figure only applies to month one.

---

What medications does each platform offer?

Ro offers more at the budget end; LifeMD offers more at the brand-name end. Both platforms offer brand-name oral Wegovy and brand injectable Wegovy access. The difference is Ro's compounded semaglutide entry point ($149/mo), which LifeMD does not offer, and LifeMD's broader brand-name menu including Wegovy HD, Ozempic off-label, Saxenda, and non-GLP-1 Triple Therapy.

Medication	LifeMD	Ro
Compounded semaglutide	❌ No longer offered	✅ $149/mo (all-inclusive)
Brand Wegovy injectable	✅ Via Novo Nordisk partnership	✅ $349/mo cash-pay
Wegovy HD (7.2mg)	✅ Available April 2026	❌
Oral Wegovy (4mg)	✅	✅
Oral Wegovy (9–25mg)	✅	Limited
Brand Zepbound (tirzepatide)	✅ $349/mo (2.5mg) via LillyDirect	✅ Via insurance
Compounded tirzepatide	❌	❌
Orforglipron (pending PDUFA April 10, 2026)	✅ $149/mo announced via LillyDirect	✅ $149/mo expected
Ozempic (off-label weight management)	✅	❌
Saxenda (liraglutide)	✅	❌
Triple Therapy (metformin + bupropion + topiramate)	✅ $129/mo	❌

On orforglipron: As of April 1, 2026, orforglipron has not yet received FDA approval. The PDUFA date is April 10, 2026. Both LifeMD and Ro have announced $149/month pricing through their respective Eli Lilly/LillyDirect pathways, contingent on approval. At $149/month, an approved orforglipron would be the first brand-name oral GLP-1 priced at parity with compounded alternatives.

On oral Wegovy: Both platforms offer oral semaglutide (Wegovy tablets). Clinical context: oral bioavailability is approximately 1% due to absorption mechanics, meaning the oral dose is substantially higher than the injectable dose to achieve comparable blood levels. Patients must take it on an empty stomach with no more than 4 ounces of water, followed by 30 minutes of fasting. This is not a casual regimen. Adherence to the dosing protocol directly affects efficacy.

---

Does LifeMD or Ro offer video consultations?

LifeMD offers video consultations; Ro does not.

LifeMD patients can access a video consultation within one hour, at $50/visit (cash pay) or copay with insurance. Asynchronous messaging is also available 24/7. For patients who want to see and speak with a provider — whether at intake to discuss a complex medical history, or during treatment to adjust dosing — LifeMD's video option is a meaningful differentiator.

Ro operates on an async-primary model. A licensed provider reviews your intake questionnaire and responds via messaging. Some video consultations are available on request, but the default pathway is text-only. There is no synchronous clinical encounter as a standard part of the Ro program. For self-directed patients who have already researched GLP-1 medications and primarily need prescription access, this is adequate. For patients with comorbidities, medication interactions, or complex clinical situations, the async-only default is a real limitation.

LifeMD charges $50/visit for video — this is in addition to the program fee and medication costs. Patients who use video consultations regularly should factor that into their total cost calculation.

---

Can LifeMD or Ro help with insurance for Wegovy?

LifeMD handles prior authorization in-house; Ro assists but does not manage the full process.

LifeMD's insurance handling:

• Accepts most major PPO plans for the GLP-1 weight loss program
• Handles prior authorization paperwork, insurer coordination, and appeals in-house
• Program fee drops to $29/mo for qualifying insured patients
• Brand Wegovy or Zepbound may cost $0–$75/mo copay with qualifying coverage
• Does not accept Medicare or Medicaid for the GLP-1 weight loss program

Ro's insurance handling:

• Added insurance navigation support in 2025
• Helps verify coverage and submit initial prior authorization requests
• Does not file appeals or manage multi-step PA denials on patients' behalf
• Compounded semaglutide program is cash-pay only — insurance does not apply
• No separate program fee; the standard Ro program structure applies

LifeMD's prior authorization handling is a substantive advantage for insured patients. Prior authorization for GLP-1 medications often involves documentation of BMI, comorbidities, prior medication failure, and appeals when initial requests are denied. LifeMD's care coordination team manages this process. Ro's insurance support assists but stops short of the full advocacy model. Patients who have tried to navigate GLP-1 prior authorization on their own understand the value of a platform that handles it.

As of April 2026, an estimated 40–50% of commercial plans cover some form of GLP-1 for weight management, though coverage terms vary significantly. If your PPO plan covers Wegovy or Zepbound, LifeMD's infrastructure is positioned to help you access that coverage. If your plan does not cover GLP-1s, or if you are on Medicare or Medicaid, Ro's lower-priced cash-pay pathway is more relevant.

---

What is LifeMD Triple Therapy vs GLP-1?

LifeMD's Triple Therapy is a non-GLP-1 oral option; Ro does not offer a comparable alternative. LifeMD offers a combination of metformin, bupropion, and topiramate — three existing medications used off-label in combination for weight management. This regimen is not a GLP-1 receptor agonist and does not carry the appetite suppression or metabolic effects associated with semaglutide or tirzepatide. It costs $129/mo at LifeMD, plus the program fee.

Triple Therapy is relevant for patients who do not qualify for GLP-1 medications, cannot tolerate GLP-1 side effects, or want a lower-cost non-injectable alternative. Evidence for this combination is more limited than for FDA-approved GLP-1 drugs. Patients considering Triple Therapy should discuss expected outcomes directly with their provider.

Ro does not offer a comparable non-GLP-1 oral alternative. Patients at Ro who cannot use GLP-1 medications have fewer pathways.

---

Who is LifeMD best for?

• Insured patients with PPO coverage for GLP-1 medications. LifeMD's program fee drops to $29/mo with qualifying insurance, and in-house prior authorization handling can make brand Wegovy or Zepbound affordable. This is LifeMD's strongest use case.
• Patients who want video consultations. The ability to speak with a provider within one hour — during intake, during dose escalation, or when managing side effects — is a meaningful clinical advantage over Ro's async-only model.
• Patients who want the broadest brand-name GLP-1 menu. Oral Wegovy (multiple doses), Wegovy HD, Zepbound, and orforglipron (pending approval) on a single platform with unified medical records.
• Patients interested in non-GLP-1 alternatives. Triple Therapy at $129/mo (plus fee) is available for patients who don't qualify for GLP-1s or want to avoid injectables at a lower cost than oral GLP-1 options.

Read our full LifeMD weight loss review for complete pricing tables and insurance details.

---

Who is Ro best for?

• Self-pay patients who want the lowest monthly cost. Compounded semaglutide at $149/month, all-inclusive, with no program fee layered on top. This is as affordable as it gets from a major, established platform.
• Patients comfortable with async-only care. If you've done your research, understand GLP-1 treatment, and primarily need prescription access rather than regular provider interaction, Ro's model is efficient.
• Patients exploring insurance while starting affordable. Ro's ability to offer compounded semaglutide while simultaneously helping with prior authorization for brand-name medications lets patients start cheap and transition within a single platform once coverage is confirmed.
• Needle-averse patients starting on oral Wegovy. Ro offers oral semaglutide through April 15 at $149/month before reverting to $199/month — a promotional window worth noting for patients who want brand-name oral GLP-1 at a low entry price.

Read our full Ro weight loss review for complete program details and medication comparisons.

---

How We Evaluated

This comparison is based on: public pricing verified directly on LifeMD and Ro websites (April 2026); clinical program details from provider public materials; medication information from FDA labels and published clinical trials; insurance navigation capabilities described in public-facing platform materials. We reviewed both providers' full medication menus, pricing structures, and care models independently. Telehealth Ally has no commercial relationship with either provider, and our evaluations are editorial-only. Revenue does not influence our rankings.

---

Frequently Asked Questions

Which is cheaper: LifeMD or Ro? For self-pay patients, Ro is cheaper. Ro's $149/month compounded semaglutide includes everything — medication, consultations, shipping — with no program fee. LifeMD charges a $75/month program fee in month one (rising to $149/month thereafter) on top of medication costs. For insured patients with qualifying PPO coverage, LifeMD can be cheaper: the program fee drops to $29/month, and brand Wegovy may cost $0/month copay.

Does LifeMD or Ro offer video consultations? LifeMD offers video consultations available within one hour, at $50/visit. Ro is async-only — the standard pathway is provider review of a questionnaire with messaging for follow-up. Some video consultations are available at Ro on request, but they are not the default.

Can LifeMD or Ro help with insurance for Wegovy? LifeMD handles prior authorization in-house, manages appeals, and accepts most major PPO plans. The program fee drops to $29/month for qualifying insured patients. Ro added insurance navigation support in 2025 and assists with PA submission, but does not manage the full appeals process. For insured patients, LifeMD's infrastructure is meaningfully more comprehensive.

What is LifeMD Triple Therapy vs GLP-1? Triple Therapy is LifeMD's non-GLP-1 oral option: a combination of metformin, bupropion, and topiramate used off-label for weight management at $129/month plus the program fee. It is not a GLP-1 receptor agonist and has a different mechanism, efficacy profile, and side effect burden than semaglutide or tirzepatide. Ro does not offer a comparable alternative.

Which has better customer support? LifeMD offers 24/7 provider messaging and video consultations within one hour. Ro offers unlimited provider messaging but no standard video option. LifeMD's model provides more synchronous access. Note: LifeMD has received some BBB complaints about billing and pricing clarity — confirm subscription and cancellation terms before enrolling. Ro's support is generally rated positively for speed, particularly around medication shipping.

Does Ro or LifeMD offer orforglipron? Both platforms have announced $149/month pricing for orforglipron through LillyDirect, contingent on FDA approval. As of April 1, 2026, approval has not yet been granted. The FDA PDUFA date is April 10, 2026. If approved, this would represent the most affordable brand-name oral GLP-1 available through either platform.

---

Related Comparisons

• LifeMD weight loss review — Full review with insurance details, pricing tables, and clinical program breakdown
• Ro weight loss review — Full review of the Body Program, compounded semaglutide, and how Ro handles insurance
• LifeMD vs Hims weight loss — LifeMD vs the other major DTC publicly traded telehealth brand
• Ro vs Hims vs Henry Meds GLP-1 — Comparing the three major budget GLP-1 platforms

---

Data Sources & Methodology

Pricing and protocol data sourced from LifeMD's and Ro's public websites, verified April 2026. LifeMD pricing verified via lifemd.com (April 1, 2026); Ro pricing verified via ro.co and current review data (April 2026). Clinical data cited from FDA product labels and published trial literature. Telehealth Ally has no commercial relationship with either provider. Rankings and ratings are editorial-only.